TCT-57: High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary interventions in acute coronary syndromes  by unknown
TUESDAY, NOVEMBER 8, 2011, 10:15 AM - 12:25 PM
(HORIZONS-AMI) study. Cox regression analysis was performed to adjust for
covariates which were significant univariate predictors of mortality.
Results: According to the WHO anemia definition, 4815 (40%) patient had baseline
anemia. The incidence of major bleeding was 3.3% in patients with anemia compared
to 0.7% in patients without anemia (p<0.001). By multivariate analysis, major bleeding
was a significant predictor of mortality (HR 1.4, 95% CI: 1.04-1.8; p=0.027) in the
total study population at 2.3 years of follow up (interquartile range 1.4 to 3.5 years).
Among patients with anemia, major bleeding remained a strong and independent
predictor of mortality (HR 1.5, 95% CI: 1.1-2.0; p=0.008). However, among patients
without anemia, major bleeding was no longer a significant predictor of mortality (HR
1.25, 95% CI: 0.52-3.03; p=0.62).
Multivariate predictors of mortality in anemic and non anemic subgroups.
Conclusion: In patients undergoing PCI with Bivalirudin therapy, major bleeding is
associated with early and long term mortality. This association is linked with and
related to baseline anemia. Further studies are needed to study this important
association.
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Background: Post-treatment platelet reactivity(PR) is associated with major adverse
cardiovascular events(MACE) following percutaneous coronary intervention(PCI) in
the clopidogrel era. Prasugrel is a new P2Y12-ADP receptor which induces a higher
platelet reactivity inhibition. We aimed to investigate the relationship between PR
following a prasugrel loading dose(LD) and thrombotic events.
Methods: A prospective multicentre study included 301 patients that had successful
PCI for an acute coronary syndrome(ACS) and received prasugrel therapy. Vasodilator-
Stimulated Phosphoprotein(VASP index) was measured after prasugrel LD. High
on-Treatment PR(HTPR) was defined as a VASP≥50%. MACE included
cardiovascular death, myocardial infarction and definite stent thrombosis at one month.
Results: The mean VASP following prasugrel LD was 34.3±23.1%. HTPR was
observed in 76 patients(25.2%). Patients experiencing a thrombotic event following
PCI had a significantly higher VASP index compared to those free of event(64.4 ±14.4
vs 33.4±22.7%; range 51–64 and 5–47.6 respectively; p=0.001). Kaplan-Meier analysis
comparing good responders and patients with HTPR demonstrated a significantly
higher rate of MACE in patients with HTPR(log rank p<0.001). Patients with minor
or major non-CABG related TIMI bleeding and those without had similar VASP index
(30±17.8 vs 34.3±23.%;p=0.7).
Conclusion: Despite the use of prasugrel a significant number of patients undergoing
PCI in the setting of acute coronary syndromes do not achieve an optimal PR inhibition.
Such patients have a higher risk of MACE following PCI.
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Background: In the TRITON-TIMI 38 study prasugrel compared to clopidogrel
reduced death, reinfarction and reinfarction in patients with STEMI undergoing
primary PCI without increasing bleeding complications. Little is known about use and
results of prasugrel in real world clinical practice.
Methods: Methods: In the prospective ATACS registry patients with STEMI < 24
hours undergoing angiography and subsequent PCI if feasible were enrolled in 27
hospitals in Germany. Timing and dosing were recorded as well as procedural features
and inhospital outcomes. Data were centrally collected and analysed.
Results: Between Oct 2009 and December 2010 a total of 1000 patients with STEMI
who underwent angiography were included. 713 (71%) were treated with clopidogrel,
287 (29%) with prasugrel. In clopidogrel treated patients a 600 mg loading was given
in 94 % and 300 mg in 5 % of the patients. Prasugrel with a loading dose of 60 mg
was administered in 95%, other loading doses in 5 % of the patients. A PCI was
performed in 924 (92 %) patients, 657 with clopidogrel and 267 with prasugrel. A stent
was implantated in 95 % of the patients with PCI. Aspirin was given in 99% of patients
and a GP IIb/IIIa inhibitor in 45 % with prasugrel and 47 % with clopidogrel. The
unadjusted in-hospital event rates in patients with PCI are shown in the table.
Inhospital events
Conclusion: In real world clinical practice prasugrel in patients with primary PCI for
STEMI is safe and associated with an improved clinical outcome compared to
clopidogrel supporting the findings of the randomized clinical trial.
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